These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 15589117

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Inter-individual variation in brain phenylalanine concentration in patients with PKU is not caused by genetic variation in the 4F2hc/LAT1 complex.
    Møller LB, Paulsen M, Koch R, Moats R, Guldberg P, Güttler F.
    Mol Genet Metab; 2005 Dec; 86 Suppl 1():S119-23. PubMed ID: 16176881
    [Abstract] [Full Text] [Related]

  • 4. Site-directed mutagenesis of cysteine residues of large neutral amino acid transporter LAT1.
    Boado RJ, Li JY, Chu C, Ogoshi F, Wise P, Pardridge WM.
    Biochim Biophys Acta; 2005 Sep 15; 1715(2):104-10. PubMed ID: 16125134
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Functional activity of a large neutral amino acid transporter (LAT) in rabbit retina: a study involving the in vivo retinal uptake and vitreal pharmacokinetics of L-phenyl alanine.
    Atluri H, Talluri RS, Mitra AK.
    Int J Pharm; 2008 Jan 22; 347(1-2):23-30. PubMed ID: 17686592
    [Abstract] [Full Text] [Related]

  • 10. Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery.
    Peura L, Malmioja K, Laine K, Leppänen J, Gynther M, Isotalo A, Rautio J.
    Mol Pharm; 2011 Oct 03; 8(5):1857-66. PubMed ID: 21770378
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Oncogenicity of L-type amino-acid transporter 1 (LAT1) revealed by targeted gene disruption in chicken DT40 cells: LAT1 is a promising molecular target for human cancer therapy.
    Ohkawa M, Ohno Y, Masuko K, Takeuchi A, Suda K, Kubo A, Kawahara R, Okazaki S, Tanaka T, Saya H, Seki M, Enomoto T, Yagi H, Hashimoto Y, Masuko T.
    Biochem Biophys Res Commun; 2011 Mar 25; 406(4):649-55. PubMed ID: 21371427
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. L-type amino acid transporters LAT1 and LAT4 in cancer: uptake of 3-O-methyl-6-18F-fluoro-L-dopa in human adenocarcinoma and squamous cell carcinoma in vitro and in vivo.
    Haase C, Bergmann R, Fuechtner F, Hoepping A, Pietzsch J.
    J Nucl Med; 2007 Dec 25; 48(12):2063-71. PubMed ID: 18056335
    [Abstract] [Full Text] [Related]

  • 16. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition.
    Uchino H, Kanai Y, Kim DK, Wempe MF, Chairoungdua A, Morimoto E, Anders MW, Endou H.
    Mol Pharmacol; 2002 Apr 25; 61(4):729-37. PubMed ID: 11901210
    [Abstract] [Full Text] [Related]

  • 17. LAT1 gene variants--potential factors influencing the clinical course of phenylketonuria.
    Bik-Multanowski M, Pietrzyk JJ.
    J Inherit Metab Dis; 2006 Oct 25; 29(5):684. PubMed ID: 16972176
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Structural properties for selective and efficient l-type amino acid transporter 1 (LAT1) mediated cellular uptake.
    Kärkkäinen J, Gynther M, Kokkola T, Petsalo A, Auriola S, Lahtela-Kakkonen M, Laine K, Rautio J, Huttunen KM.
    Int J Pharm; 2018 Jun 10; 544(1):91-99. PubMed ID: 29669256
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.